Bambusa Therapeutics

BBTXNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$646.190 M

$16.00 +6.74%

Close of 3 Nov 2026

As of 3 Nov 2026, Bambusa Therapeutics (BBTX) has a market capitalization of $646.2M. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

—

Not reported

Earnings

—

Not reported

Shares outstanding

—

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 164 →

#53SL ScienceSLBT$712.2M
#54Attovia TherapeuticsATTO$687.1M
#55Bambusa TherapeuticsBBTX$646.2M
#56Solid BiosciencesSLDB$643.4M
#57Ginkgo BioworksDNA$633.8M

Insiders buying

All insider buying →

2 open-market purchases by officers and directors of Bambusa Therapeutics, worth $12.0M. Grants and option exercises are excluded.

Helmut Wolfgang Jeggle$6.00M
375,000 shares at $16.00 on 2 Nov 2026 · filed 2 Nov 2026
Salvia Investment GmbH$6.00M
375,000 shares at $16.00 on 2 Nov 2026 · filed 2 Nov 2026

What if Bambusa Therapeutics were worth as much as…

Open the what-if tool →

Gold $27.4T

$677,252.09

Per share 42,328× higher

Bitcoin $1.54T

$38,091.86

Per share 2,381× higher

Apple $4.94T

$122,255.14

Per share 7,641× higher

Or at a round number

$1.00B $2.00B $5.00B $10.0B

Where these numbers come from

Share counts and financials for Bambusa Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.